Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Baldo Scassellati Sforzolini
Unlocking Approval: Baldo Scassellati Sforzolini from Galderma in a Stimulating Dialogue Exchange with PharmaShots
Shots:  Galderma’s Nemluvio (nemolizumab) was recently approved by the US FDA for the treatment of adults with prurigo nodularis, following positive Phase III results from the OLYMPIA study.  Today at PharmaShots, we have Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma, to discuss the study’s design and the potential of Nemluvio in…
October 23, 2024
Viewpoints_Mark Mikhael
Enhancing Accessibility: Mark Mikhael from Olympia Pharmaceuticals in a Riveting Conversation with PharmaShots
Shots:  Compounding pharmacies can help significantly by providing customized medications tailored to individual patient needs, bridging the gap in medicine delivery during a drug shortage, and enhancing accessibility.   Today, at PharmaShots, we have Mark Mikhael, CEO of Olympia Pharmaceuticals, an FDA-registered 503B outsourcing facility.  Currently licensed in 47 states of the US, Olympia hosts two…
October 21, 2024
Viewpoints_Yelak Biru
Fund Raising Initiative: Yelak Biru from International Myeloma Foundation in Conversation with PharmaShots
Shots:   As a fund-raising initiative, the International Myeloma Foundation began a 3-day, 2-night cycling expedition from Aug 29thto Sep 3rd  The initiative supports patient education, advocacy, and next-gen research to advance a cure for multiple myeloma  Today, at PharmaShots we have Yelak Biru, President and CEO of the International Myeloma Foundation, shedding light on this…
October 16, 2024
Viewpoints_Stella Sarraf
Enhancing Neurodegenerative Care: Stella Sarraf from Spinogenix in an Enlightening Dialogue Exchange with PharmaShots
Shots:  With a broad portfolio of candidates in ALS, Alzheimer’s disease, Schizophrenia, and Fragile X Syndrome, Spinogenix initiated the P-II study evaluating SPG302 for the treatment of patients with Alzheimer’s disease  SPG302, a synaptic regenerative therapy, is aimed to provide an effective and patient-friendly solution as a daily pill for ALS and Alzheimer’s disease  Today…
October 14, 2024
Viewpoints_Maria Belvisi_Dr. Sarah Doffman_Dr. Janet Franklin
ATS 2024: Maria Belvisi, Sarah Doffman, and Janet Franklin from AstraZeneca & Amgen in a Stimulating Conversation with PharmaShots
Shots:  Jointly developed by AstraZeneca & Amgen, AZD8630/AMG targets Thymic stromal lymphopoietin (TSLP), an epithelial cytokine involved in Chronic Inflammatory Disorders  Recently, AstraZeneca and Amgen released the P-I data evaluating AZD8630/AMG104 on three doses vs. placebo for 28 days. The data demonstrated linear PK at all three doses  Today, at PharmaShots we have Prof. Maria…
October 7, 2024
Viewpoints_Robert Fogel_Dave Singh
AstraZeneca at ATS’24: Robert Fogel & Dave Singh in a Stimulating Conversation with PharmaShots
Shots:  Cardiopulmonary events associated with COPD are responsible for an increasing mortality rate in COPD patients. ETHOS trial, a posthoc analysis navigates BGF’s impact on a wide range of cardiopulmonary outcomes beyond COPD exacerbations  The post-hoc analysis reveals that AstraZeneca’s Breztri led to a 20% reduction in the risk of severe cardiopulmonary events. AstraZeneca is currently…
September 30, 2024
Viewpoints_Sofie Berg
Unlocking Approval: Sofie Berg from AbbVie in an Illuminating Dialogue Exchange with PharmaShots
Shots:  Recently, the European Commission approved AbbVie’s Skyrizi for the treatment of adults with moderate to severe active Ulcerative Colitis  The approval was based on positive data from the P-III INSPIRE induction trial and COMMAND maintenance study   Today, at PharmaShots we have Sofie Berg, the therapeutic area head of international immunology, International Medical Affairs, at…
September 23, 2024
Viewpoints_Jacqueline Nielsen_Tahi Ahmadi
Unlocking Approval: Jacqueline Nielsen from AbbVie & Tahi Ahmadi from Genmab in a Riveting Conversation with PharmaShots
Shots:  Recently, the EMA’s CHMP adopted a positive opinion by recommending conditional marketing authorization for AbbVie and Genmab’s Tepkinly for the treatment of R/R Follicular Lymphoma  Today at PharmaShots, we have Jacqueline Nielsen, Head of Hematologic Oncology Affairs at AbbVie, and Tahi Ahmadi, EVP and CMO at Genmab, shedding light on this conditional marketing authorization…
September 18, 2024
Viewpoints_Ahsan Arozullah
Astellas at ASCO 2024: Ahsan Arozullah in an Illuminating Dialogue Exchange with PharmaShots
Shots:  At ASCO 2024, Astellas Pharma presented 16 abstracts across several types of cancers with unmet medical needs  Today at PharmaShots, we have Ahsan Arozullah Sr. VP, Head of Oncology Development, shedding light on the advancement Astellas’ oncology portfolio for urothelial carcinoma, gastric cancer, and prostate cancer  Ahsan talks about the presented results from studies…
September 16, 2024
Load more